Edaravone dextrocanol sodium can treat acute cerebral infarction. Edaravone dextranol sodium is a compound preparation of edaravone and dextranol, which is used to improve the neurological symptoms caused by acute ischemic stroke, and to improve the ability to perform activities of daily living and dysfunction, and is one of the medicines used for the treatment of acute cerebral infarction. Edaravone, one of the commonly used drugs for cerebral infarction, acts as a cerebroprotective agent, scavenging oxygen free radicals, increasing local cerebral blood flow around the infarction, stopping the progression of cerebral edema and cerebral infarction, and relieving the accompanying neurological symptoms and inhibiting delayed neuronal death. Dexcamptol is a bicyclic monoterpene whose mechanism of action is to inhibit the expression of inflammatory factors during cerebral infarction, thereby reducing brain cell death. Edaravone dextrocanol sodium is contraindicated in severe renal failure, hypersensitivity to ingredients, and with caution in patients with renal insufficiency, hepatic insufficiency, cardiac disease, and advanced age >80 years. Edaravone dextranol sodium, as a compound preparation of edaravone and dextranol, possesses the efficacy of the two at the same time and can be used for the treatment of acute cerebral infarction. It is recommended that the condition of patients with cerebral infarction be assessed by a medical professional to develop an individualized treatment plan.